-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 8th SciNeuro Pharmaceuticals announced the official launch and completion of a $100m round of A financing, focusing on the development of innovative drugs for patients with central nervous system (CNS) diseases.
round of financing is jointly led by Lilly Asia Fund and Arch Venture Partners, followed by Boyu Capital, General Atlantic, Sequoia Capital China, Taifu Capital and Zoo Capital.
will be used to build and develop the CNS portfolio, with the initial focus on Greater China.
according to the press release, Dr. Limin is a renowned neuroscientist who previously served as a professor at Johns Hopkins University School of Medicine and senior vice president of a major international pharmaceutical company and head of global research and development in neuroscience.
is also a founding partner of Lilly Asia.
addition, the core team of Saisan Pharma includes Dr. Qiuqing Ang, Chief Medical Officer, Dr. Danny Chen, Senior Vice President and Director of Translational Sciences, and Dr. Paul Stead, Chief Commercial Officer.
: sciNeuro Pharmaceuticals Launches to Bring Innovative Treatments for CNS Diseases.Retrieved Dec 8,2020, from | Sessoms Pharma completed a $100 million round of A-round financing.Retrieved Dec 10,2020, from Lilly Asia Capital Source: Pharmaceutical Mission Hills